Accelerated-phase MPNs: mutational landscape, challenges, and novel treatment strategies being explored

Patients with BCR-ABL negative myeloproliferative neoplasms (MPNs) are at risk of progressing to accelerated-phase or blast-phase disease (MPN-AP/BP). Several mutations, including ASXL1, EZH2, and TP53, are involved in progression to MPN-AP/BP, and there are a number of challenges with treating patients who progress to this stage. In this podcast, Anand Patel, MD, University of Chicago, Chicago, IL, Andrew Kuykendall, MD, Moffitt Cancer Center, Tampa, FL, and Jan Philipp Bewersdorf, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discuss the mutational landscape of MPN-AP, and further highlight challenges with treating patients. The experts also comment on novel therapeutic strategies being explored in this space. The post Accelerated-phase MPNs: mutational landscape, challenges, and novel treatment strategies being explored appeared first on VJHemOnc.